Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines

BACKGROUND: The anti-leukemic mechanism of homoharringtonine (HHT) differs from that of IM, and HHT is one of the most useful agents for use in patients with IM resistance or intolerance. The Bcl-6/p53 pathway has been shown to regulate the sensitivity of tumor cells to antitumor drugs. We tested wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qian, Ding, Wei, Ding, Yihan, Ma, Jingjing, Qian, Zhaoye, Shao, Jingxian, Li, Yufeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514933/
https://www.ncbi.nlm.nih.gov/pubmed/28410239
http://dx.doi.org/10.18632/oncotarget.16731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514933/
https://www.ncbi.nlm.nih.gov/pubmed/28410239
http://dx.doi.org/10.18632/oncotarget.16731

Ejemplares similares